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Hematogones are normal B-cell precursors that are 
observed in small numbers in the bone marrow; how-
ever, significant expansion of hematogones can occur 
in the bone marrow in healthy newborns, and in indi-
viduals  with  malignant  and  non-malignant  hemato-
logic disorders, including congenital and autoimmune 
cytopenias, nutritional anemias, viral infections,  and   
Gaucher disease [1-6]. Morphologically, hematogones 
are small- to medium-sized cells with condensed chro-
matin and scant cytoplasm devoid of inclusions and 
vacuoles;  some  hematogones  resemble  leukemic 
lymphoblasts. As the morphological and immunophe-
notypical features of hematogones are similar to those 
of the blasts in precursor B acute lymphoblastic leuke-
mia  (ALL),  sometimes  diagnostic  problems  arise. 
Using flow cytometry hematogones can be identified 
by their peculiar antigenic profile; 3 forms are defined 
on the basis of their maturational stage [1-6]. 
Stage  1  hematogones  are  the  most  immature 
form, and along with CD34 and TdT positivity they 
exhibit dimmer expression of CD45 and CD19, and 
brighter  expression  of  CD10,  as  compared  to  the 
more mature forms and normal lymphocytes. Stage 
1  hematogones  lack  CD20.  Stage  2  hematogones 
represent the majority of the hematogone popula-
tion. They exhibit high CD34 and TdT experession, 
with increased expression of CD19, dim expression 
of  CD20,  and  gradually  decreasing  expression  of 
CD10. As they mature to stage 3 they exhibit brighter 
expression of CD20 and CD45, and dimmer expres-
sion of CD10, as compared to the more immature 
forms of hematogones. Recently, stage 3 and some 
stage 2 hematogones were reported to express CD5 
concomitantly  with  CD19  and  CD10.  Dim  expres-
sion of CD22 and bright expression of CD38 are seen 
in each hematogone stage [7].
A 1-year-old girl presented with a cough and a 
rash  on  her  body  1  d  after  developing  fever.  Her 
medical and family histories were non-contributory. 
On physical examination she had petechiae all over 
her  body  and  on  both  tonsils.  She  did  not  have 
organomegaly.  The  remaining  systemic  examina-
tions  were  normal.  Her  complete  blood  count 
results  were  as  follows:  hemoglobin:  9.3  g  dL-1; 
hematocrit:  27%;  erythrocyte  count:  4.01x109  L-1; 
mean corpuscular volume: 69 fL; red cell distribution 
width: 15.5%; white blood cell count: 14,100 mm-3; 
platelet count: 2000 mm-3. There were 80% lympho-
cytes, 20% neutrophils, 1 or 2 platelets without aggre-
gation, and hypochromic microcytic erythrocytes on peripheral blood smear. We observed 12% mononu-
clear  cells  resembling  lymphoblasts  (Figure  1). 
Immunophenotypic  analysis  of  her  bone  marrow 
was performed using flow cytometry. Total lymphoid 
cells  were  selected  using  SSC  versus  FSC  gating 
(Figure 2a). B-lymphoid cells (48%-49% of total lym-
phocytes) expressing CD19 and CD22 were observed. 
Among all the lymphocytes (Figure 2a), those consti-
tuting 38% that showed bright CD10 expression, and   
coexpression  of  CD19  and  CD5  (Figure  2b  and  c) 
were considered as hematogones. 
A small number (approximately 4%) of cells that 
were probably early-stage or stage 1 hematogones 
also  expressed  CD34  and  TdT  (Figure  2d  and  e). 
These  cells  lacked  aberrant  marker  expression. 
Serology was positive for rubella virus immunoglobu-
lin M. Iron panel of the patient showed iron deficiency 
anemia (serum iron level: 20.6 µg dL-1; serum iron 
binding capacity: 460 µg dL-1; transferrin saturation: 
5.8%; ferritin: 5.8 ng dL-1) and complete blood count 
parameters in both of the patient’s parents were nor-
mal. As such, rubella virus-associated immune throm-
bocytopenic purpura was considered as the patient’s 
diagnosis, in addition to iron deficiency anemia. 
The patient was given intravenous immunoglob-
ulin (2 g kg-1) and ferrous sulphate treatments. An 
significant  increase  in  her  platelet  count  was 
observed within 2 days. A follow up bone marrow 
smear performed 2 days after the first one or imme-
diately following the therapy showed a decrease in 
the number of hematogones (3%) by morphological 
examination as compared to the previous analysis. 
But  flow  cytometric  analysis  of  the  second  bone 
marrow  sample  was  not  performed/done  at  that 
time. She was discharged with a platelet count of 
153,000  mm-3.  One  month  later  her  hemoglobin 
increased  to  12  g  dL-1,  and  the  ferrous  sulphate 
dose was decreased accordingly. She received iron 
therapy for a total of 3 months starting from her hos-
pitalisation. During 6 months of follow-up her throm-
bocyte  count  fluctuated  between  112,000  and 
451,000 mm-3. 
The presented patient had rubella virus-associat-
ed  thrombocytopenia  and  iron  deficiency  anemia; 
both conditions are reported to be associated with 
the appearance of hematogones [7]. Once the diag-
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Figure 1. Hematogones with blast-like features in the bone 
marrow sample
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ed, rapid improvement of thrombocytopenia along 
with a striking reduction in bone marrow hemato-
gones  was  observed.  The  cause  of  the  observed 
rapid reduction in hematogones is not clear, but may 
have  been  due  to  their  differentiation  into  more 
mature forms-probably due to the effect of high-dose 
intravenous immunoglobulin and/or iron therapy. 
Hematogones are B-cell precursors that exhibit a 
continuous and complete maturation spectrum. In 
the  presented  case  stage  2  hematogones  com-
prised the majority of the hematogone population, 
as was reported in most other cases [7]. The most 
mature stage 3 hematogones resemble mature lym-
phocytes  and  frequently  remain  unrecognized, 
whereas less mature forms-predominantly stage 1 
and some stage 2 hematogones-resemble blasts of 
ALL. In the morphological examination of the sec-
ond  bone  marrow,  we    observed  a  significant 
decrease in the percentage of blast-like cells which 
were identified as stage 1 and some stage 2 hema-
togones  (12%)  by  immunophenotypic  analysis  of 
the first marrow specimen. This prompt fall in the 
number of blast-like cells may be explained by the 
maturation  of  those  early  stage  hematogones    to 
stage 3 ones which are difficult to differentiate by 
histopathological examination of a marrow smear.
In  conclusion,  excessive  hematogones  in  the 
bone marrow of children may cause problems in 
diagnostically  differentiating  acute  lymphoblastic 
leukemia from a benign hematogone proliferative 
state, and flow cytometric analysis may help differ-
entiate these 2 cell populations. 
Written informed consent was obtained from the 
patient.
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Figure 2. a. On the SSC-FSC scatter plot we gated the total lymphocyte 
population. b. In the SSC versus CD10 plot there were 3 different popula-
tions of hematogones (in stage 1, stage 2, and stage 3, shown with ar-
rows) with very low side scatter and variable expression of CD10. c. He-
matogones with bright expression of CD19 and CD5. d. Cells shown with 
arrows are early-stage or stage 1 hematogones with CD10 and CD34, as 
well as stage 2 hematogones expressing CD10, but lacking CD34. e. Early 
hematogones expressing TdT (arrow)
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